Higher IOP may be marker for CVD

Article

Higher IOP may be a predictable marker of cardiovascular disease (CVD) in some individuals, according to a study from South Korea.

Higher IOP may be a predictable marker of cardiovascular disease (CVD) in some individuals, according to a study from South Korea published in the British Journal of Ophthalmology. The researchers found that higher IOP is associated with the presence of coronary artery calcium (CAC) in asymptomatic patients, regardless of the presence of usual cardiovascular risk factors.

The researchers’ cross-sectional study included 10,732 men and women without diagnoses of CVD or glaucoma. They measured CAC using cardiac computed tomography and IOP using a non-contact tonometer and automatic air puff control.

The researchers detected CAC in 13.7% in men and 4.3% of women. They found that increasing levels of right IOP were significantly associated with an increased prevalence of CAC. They adjusted for multiple factors - age, sex, tobacco use, alcohol use, physical activity, body mass index, educational level, centre, family history of CVD, use of dyslipidemia medication, diabetes, hypertension, total cholesterol level, high-density lipoprotein cholesterol and triglycerides - and found that the odds ratios for CAC score >0, comparing 2–4 quartiles of the right IOP with the lowest quartiles, were 1.32, 1.20 and 1.28, respectively. The associations were the same among the clinically relevant subgroups.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.